An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance

To investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED treatment profiles among those with an ED diagnosis. A cross-sectional claims analysis was conducted using the IBM MarketScan Commercial Database, a...

Full description

Saved in:

Bibliographic Details
Published in:	Urology (Ridgewood, N.J.) Vol. 149; pp. 140 - 145
Main Authors:	Burnett, Arthur L., Rojanasarot, Sirikan, Amorosi, Stacey L.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.03.2021
Subjects:	Cross-Sectional Studies Erectile Dysfunction - economics Erectile Dysfunction - epidemiology Erectile Dysfunction - therapy Health Benefit Plans, Employee - economics Health Benefit Plans, Employee - statistics & numerical data Humans Insurance Claim Review - statistics & numerical data Insurance Coverage - economics Insurance Coverage - statistics & numerical data Male Middle Aged Penile Implantation - economics Penile Implantation - statistics & numerical data Phosphodiesterase 5 Inhibitors - economics Phosphodiesterase 5 Inhibitors - therapeutic use Prevalence
ISSN:	0090-4295, 1527-9995, 1527-9995
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	To investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED treatment profiles among those with an ED diagnosis. A cross-sectional claims analysis was conducted using the IBM MarketScan Commercial Database, a nationally representative sample of US workers enrolled in ESHI plans. Patients aged 18-64 with at least one ED medical diagnosis claim and continuous enrollment in a given year between 2009 and 2017 were included. Among those with an ED diagnosis, utilization rates of the following ED treatments were determined: phosphodiesterase type 5 inhibitors (PDE5I), penile prosthesis implantation, other ED treatments (eg, vacuum pump, intraurethral suppositories), combination treatment, and no insurer-paid treatments. Between 2009 and 2017, the annual prevalence of men with ESHI suffering from ED increased by 116%. However, in 2017, only 23% of men with an ED diagnosis received an ED therapy paid for by their ESHI plans. The proportion of men taking PDE5Is ranged from 18% in 2012 to 26% in 2015. The proportion of men with ED undergoing penile prosthesis implantation has declined in recent years (0.23% in 2009 to 0.11% in 2017). Similarly, the rate of men who received other ED treatments or combination treatment has decreased from 2009 to 2017 (0.94%-0.30% and 0.65%-0.19%, respectively). ED prevalence among men insured by an ESHI plan has notably increased, yet approximately three-quarters of these men had no claims for ED treatments, indicating substantial access gaps to treatment.
AbstractList	To investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED treatment profiles among those with an ED diagnosis. A cross-sectional claims analysis was conducted using the IBM MarketScan Commercial Database, a nationally representative sample of US workers enrolled in ESHI plans. Patients aged 18-64 with at least one ED medical diagnosis claim and continuous enrollment in a given year between 2009 and 2017 were included. Among those with an ED diagnosis, utilization rates of the following ED treatments were determined: phosphodiesterase type 5 inhibitors (PDE5I), penile prosthesis implantation, other ED treatments (eg, vacuum pump, intraurethral suppositories), combination treatment, and no insurer-paid treatments. Between 2009 and 2017, the annual prevalence of men with ESHI suffering from ED increased by 116%. However, in 2017, only 23% of men with an ED diagnosis received an ED therapy paid for by their ESHI plans. The proportion of men taking PDE5Is ranged from 18% in 2012 to 26% in 2015. The proportion of men with ED undergoing penile prosthesis implantation has declined in recent years (0.23% in 2009 to 0.11% in 2017). Similarly, the rate of men who received other ED treatments or combination treatment has decreased from 2009 to 2017 (0.94%-0.30% and 0.65%-0.19%, respectively). ED prevalence among men insured by an ESHI plan has notably increased, yet approximately three-quarters of these men had no claims for ED treatments, indicating substantial access gaps to treatment. To investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED treatment profiles among those with an ED diagnosis.OBJECTIVETo investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED treatment profiles among those with an ED diagnosis.A cross-sectional claims analysis was conducted using the IBM MarketScan Commercial Database, a nationally representative sample of US workers enrolled in ESHI plans. Patients aged 18-64 with at least one ED medical diagnosis claim and continuous enrollment in a given year between 2009 and 2017 were included. Among those with an ED diagnosis, utilization rates of the following ED treatments were determined: phosphodiesterase type 5 inhibitors (PDE5I), penile prosthesis implantation, other ED treatments (eg, vacuum pump, intraurethral suppositories), combination treatment, and no insurer-paid treatments.METHODSA cross-sectional claims analysis was conducted using the IBM MarketScan Commercial Database, a nationally representative sample of US workers enrolled in ESHI plans. Patients aged 18-64 with at least one ED medical diagnosis claim and continuous enrollment in a given year between 2009 and 2017 were included. Among those with an ED diagnosis, utilization rates of the following ED treatments were determined: phosphodiesterase type 5 inhibitors (PDE5I), penile prosthesis implantation, other ED treatments (eg, vacuum pump, intraurethral suppositories), combination treatment, and no insurer-paid treatments.Between 2009 and 2017, the annual prevalence of men with ESHI suffering from ED increased by 116%. However, in 2017, only 23% of men with an ED diagnosis received an ED therapy paid for by their ESHI plans. The proportion of men taking PDE5Is ranged from 18% in 2012 to 26% in 2015. The proportion of men with ED undergoing penile prosthesis implantation has declined in recent years (0.23% in 2009 to 0.11% in 2017). Similarly, the rate of men who received other ED treatments or combination treatment has decreased from 2009 to 2017 (0.94%-0.30% and 0.65%-0.19%, respectively).RESULTSBetween 2009 and 2017, the annual prevalence of men with ESHI suffering from ED increased by 116%. However, in 2017, only 23% of men with an ED diagnosis received an ED therapy paid for by their ESHI plans. The proportion of men taking PDE5Is ranged from 18% in 2012 to 26% in 2015. The proportion of men with ED undergoing penile prosthesis implantation has declined in recent years (0.23% in 2009 to 0.11% in 2017). Similarly, the rate of men who received other ED treatments or combination treatment has decreased from 2009 to 2017 (0.94%-0.30% and 0.65%-0.19%, respectively).ED prevalence among men insured by an ESHI plan has notably increased, yet approximately three-quarters of these men had no claims for ED treatments, indicating substantial access gaps to treatment.CONCLUSIONED prevalence among men insured by an ESHI plan has notably increased, yet approximately three-quarters of these men had no claims for ED treatments, indicating substantial access gaps to treatment.
Author	Amorosi, Stacey L. Burnett, Arthur L. Rojanasarot, Sirikan
Author_xml	– sequence: 1 givenname: Arthur L. surname: Burnett fullname: Burnett, Arthur L. email: aburnet1@jhmi.edu organization: Johns Hopkins University School of Medicine, Baltimore, MD – sequence: 2 givenname: Sirikan surname: Rojanasarot fullname: Rojanasarot, Sirikan email: sirikan.rojanasarot@bsci.com organization: Boston Scientific, Marlborough, MA – sequence: 3 givenname: Stacey L. surname: Amorosi fullname: Amorosi, Stacey L. organization: Boston Scientific, Marlborough, MA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33309705$$D View this record in MEDLINE/PubMed
BookMark	eNqNkUFvEzEQhS1URNPCTwD5yGWDd722YyGEojSllYo40Iqj5XjH1MFrp_Yu0p7543WU9NJLOXnkee-N9L4zdBJiAITe12Rek5p_2s7HFH38Pc0b0pS_ek5Y_QrNataISkrJTtCMEEmqtpHsFJ3lvCWEcM7FG3RKKSVSEDZD_5YBL4P2U3YZR4s1XsW-h2Sc9vhCD3qjM-AY8HAP-G4_WrxOYAbnAV9M2Y6hzGV_m0APPYQhYxsT_g4B_3LDPV73Ox8nSNXPXQw5JujwFWhfNtchj0kHA2_Ra6t9hnfH9xzdXa5vV1fVzY9v16vlTWVazoeq5kRr0QlrqRa2axndLCxtgS00FdTKRnSGC9YtioZLxjhlhuoFl63UTLaanqOPh9xdig8j5EH1LhvwXgeIY1ZNKwhpmBSLIv1wlI6bHjq1S67XaVJPxRXB54PApJhzAquMG_S-iSFp51VN1B6T2qojJrXHpOpaFUzFzZ65nw685Pt68EGp6a-DpLJxUCrs3J6J6qJ7MeHLswTjXXBG-z8w_Yf_EcXAxWo
CitedBy_id	crossref_primary_10_1016_j_urology_2021_05_037 crossref_primary_10_1038_s41443_024_00903_9 crossref_primary_10_1093_jsxmed_qdaf224 crossref_primary_10_1016_j_urology_2024_10_053 crossref_primary_10_1016_j_arth_2023_08_062 crossref_primary_10_1007_s00345_025_05559_8 crossref_primary_10_1016_j_arth_2024_04_061 crossref_primary_10_1016_j_arth_2023_10_053 crossref_primary_10_1177_15579883241290714 crossref_primary_10_1007_s11606_024_09004_1 crossref_primary_10_1016_j_arth_2024_01_020 crossref_primary_10_1097_JU9_0000000000000190 crossref_primary_10_3390_jcm14072386 crossref_primary_10_7759_cureus_55637 crossref_primary_10_1097_JOM_0000000000002449 crossref_primary_10_3389_fruro_2025_1500839 crossref_primary_10_1016_j_jhsa_2022_06_018
Cites_doi	10.1111/jsm.12647 10.1136/postgradmedj-2016-134073 10.1016/j.jsxm.2016.01.016 10.1016/j.juro.2018.05.004 10.1016/j.jval.2018.04.987 10.1016/j.amjmed.2006.06.010 10.21037/tau.2019.08.33 10.1111/ijcp.13384 10.1038/nrdp.2016.3 10.1016/j.urology.2016.12.031 10.1016/j.juro.2018.02.980 10.1080/17434440.2019.1598259 10.12688/f1000research.16576.1 10.1016/j.sxmr.2018.11.007 10.1111/ijcp.12908 10.21037/tau.2016.12.06
ContentType	Journal Article
Copyright	2021 The Authors Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: 2021 The Authors – notice: Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.urology.2020.11.051
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1527-9995
EndPage	145
ExternalDocumentID	33309705 10_1016_j_urology_2020_11_051 S0090429520314886
Genre	Journal Article
GrantInformation_xml	– fundername: Boston Scientific funderid: https://doi.org/10.13039/100008497
GroupedDBID	--- --K --M -RU .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAEJM AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJJEV AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEA HMK HMO HVGLF HZ~ IHE J1W KOM L7B LZ2 M29 M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SPCBC SSH SSZ T5K UV1 WH7 WOW WUQ X7M XPP Z5R ZGI ~G- ~HD 6I. AACTN AAFTH AAIAV ABLVK ABYKQ ACRZS AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW LCYCR RIG ZA5 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c466t-160aa7d7ff3a7fd453b8f34e58a373f927dc675d87d76955635c3a86949a594a3
ISICitedReferencesCount	22
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000627885200041&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0090-4295 1527-9995
IngestDate	Sun Nov 09 09:47:18 EST 2025 Wed Feb 19 02:28:08 EST 2025 Sat Nov 29 07:21:16 EST 2025 Tue Nov 18 22:54:52 EST 2025 Fri Feb 23 02:45:12 EST 2024 Tue Oct 14 19:30:52 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Language	English
License	This is an open access article under the CC BY license. Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c466t-160aa7d7ff3a7fd453b8f34e58a373f927dc675d87d76955635c3a86949a594a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://dx.doi.org/10.1016/j.urology.2020.11.051
PMID	33309705
PQID	2470025978
PQPubID	23479
PageCount	6
ParticipantIDs	proquest_miscellaneous_2470025978 pubmed_primary_33309705 crossref_citationtrail_10_1016_j_urology_2020_11_051 crossref_primary_10_1016_j_urology_2020_11_051 elsevier_sciencedirect_doi_10_1016_j_urology_2020_11_051 elsevier_clinicalkey_doi_10_1016_j_urology_2020_11_051
PublicationCentury	2000
PublicationDate	March 2021 2021-03-00 20210301
PublicationDateYYYYMMDD	2021-03-01
PublicationDate_xml	– month: 03 year: 2021 text: March 2021
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Urology (Ridgewood, N.J.)
PublicationTitleAlternate	Urology
PublicationYear	2021
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Selvin, Burnett, Platz (bib0002) 2007; 120 Chung (bib0017) 2017; 6 Burnett, Nehra, Breau (bib0001) 2018; 200 Berchick, Barnett, Upton (bib0004) 2019 IBM Watson Health. IBM MarketScan research databases for life sciences researchers. Available at Burnett, Zhong, Amorosi (bib0010) 2018; 21 Hatzimouratidis, Salonia, Adaikan (bib0014) 2016; 13 Munk, Knudsen, Comerma-Steffensen, Simonsen (bib0016) 2019; 7 Goldstein, Goren, Li (bib0008) 2019; 73 Houman, Eleswarapu, Mills (bib0015) 2020; 9 Krzastek, Bopp, Smith, Kovac (bib0013) 2019; 8 Accessed December 22, 2020. Frederick, Cakir, Arora (bib0011) 2014; 11 Mazur DJ, McBride (bib0005) 2018; 199 U.S. Centers for Medicare & Medicaid Services. National coverage determination (NCD) for diagnosis and treatment of impotence (230.4). Publication Number 100-3 (Version 1). Available at Mobley, Khera, Baum (bib0012) 2017; 93 U.S. Census Bureau. Employer-based health insurance by sex by age.Available at Yafi, Jenkins, Albersen (bib0020) 2016; 2 Dick, Tsambarlis, Reddy, Hellstrom (bib0019) 2019; 16 Mulhall, Luo, Zou (bib0003) 2016; 70 Le, McAchran, Paolone (bib0007) 2017; 102 Frederick (10.1016/j.urology.2020.11.051_bib0011) 2014; 11 Hatzimouratidis (10.1016/j.urology.2020.11.051_bib0014) 2016; 13 Mobley (10.1016/j.urology.2020.11.051_bib0012) 2017; 93 Yafi (10.1016/j.urology.2020.11.051_bib0020) 2016; 2 Le (10.1016/j.urology.2020.11.051_bib0007) 2017; 102 Krzastek (10.1016/j.urology.2020.11.051_bib0013) 2019; 8 Burnett (10.1016/j.urology.2020.11.051_bib0010) 2018; 21 Munk (10.1016/j.urology.2020.11.051_bib0016) 2019; 7 Mazur DJ (10.1016/j.urology.2020.11.051_bib0005) 2018; 199 Houman (10.1016/j.urology.2020.11.051_bib0015) 2020; 9 Goldstein (10.1016/j.urology.2020.11.051_bib0008) 2019; 73 Mulhall (10.1016/j.urology.2020.11.051_bib0003) 2016; 70 Berchick (10.1016/j.urology.2020.11.051_bib0004) 2019 Burnett (10.1016/j.urology.2020.11.051_bib0001) 2018; 200 Chung (10.1016/j.urology.2020.11.051_bib0017) 2017; 6 Dick (10.1016/j.urology.2020.11.051_bib0019) 2019; 16 Selvin (10.1016/j.urology.2020.11.051_bib0002) 2007; 120 10.1016/j.urology.2020.11.051_bib0006 10.1016/j.urology.2020.11.051_bib0009 10.1016/j.urology.2020.11.051_bib0018
References_xml	– volume: 200 start-page: 633 year: 2018 end-page: 641 ident: bib0001 article-title: Erectile dysfunction: AUA guideline publication-title: J Urol – volume: 102 start-page: 126 year: 2017 end-page: 129 ident: bib0007 article-title: Assessing the variability in insurance coverage transparency for male sexual health conditions in the United States publication-title: Urology – reference: . Accessed December 22, 2020. – reference: IBM Watson Health. IBM MarketScan research databases for life sciences researchers. Available at: – volume: 199 start-page: e390 year: 2018 end-page: e391 ident: bib0005 article-title: PD18-03 Doomed to impotence: analysis of erectile dysfunction (ED) and inflatable penile prosthesis (IPP) insurance coverage from verification benefits databases publication-title: J Urol – volume: 6 start-page: 37 year: 2017 end-page: 45 ident: bib0017 article-title: Penile prosthesis implant: scientific advances and technological innovations over the last four decades publication-title: Transl Androl Urol – volume: 2 start-page: 16003 year: 2016 ident: bib0020 article-title: Erectile dysfunction publication-title: Nat Rev Dis Primers – volume: 13 start-page: 465 year: 2016 end-page: 488 ident: bib0014 article-title: Pharmacotherapy for erectile dysfunction: recommendations from the fourth international Consultation for Sexual Medicine (ICSM 2015) publication-title: J Sex Med – volume: 73 start-page: e13384 year: 2019 ident: bib0008 article-title: The association of erectile dysfunction with productivity and absenteeism in eight countries globally publication-title: Int J Clin Pract – volume: 9 start-page: S116 year: 2020 end-page: S122 ident: bib0015 article-title: Current and future trends in men's health clinics publication-title: Transl Androl Urol – reference: U.S. Centers for Medicare & Medicaid Services. National coverage determination (NCD) for diagnosis and treatment of impotence (230.4). Publication Number 100-3 (Version 1). Available at: – volume: 11 start-page: 2546 year: 2014 end-page: 2553 ident: bib0011 article-title: Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients publication-title: J Sex Med – volume: 8 start-page: F1000 year: 2019 ident: bib0013 article-title: Recent advances in the understanding and management of erectile dysfunction publication-title: F1000Res – volume: 16 start-page: 281 year: 2019 end-page: 286 ident: bib0019 article-title: An update on: long-term outcomes of penile prostheses for the treatment of erectile dysfunction publication-title: Expert Rev Med Devices – reference: U.S. Census Bureau. Employer-based health insurance by sex by age.Available at: – volume: 21 start-page: S143 year: 2018 ident: bib0010 article-title: PIH15: the economic burden of erectile dysfunction and related comorbidities: a Medicare perspective publication-title: Value Health – volume: 70 start-page: 1012 year: 2016 end-page: 1018 ident: bib0003 article-title: Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA publication-title: Int J Clin Pract – volume: 93 start-page: 679 year: 2017 end-page: 685 ident: bib0012 article-title: Recent advances in the treatment of erectile dysfunction publication-title: Postgrad Med J – volume: 7 start-page: 430 year: 2019 end-page: 441 ident: bib0016 article-title: Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails publication-title: Sex Med Rev – year: 2019 ident: bib0004 article-title: Current Population Reports, P60-267(RV), Health Insurance Coverage in the United States: 2018 – volume: 120 start-page: 151 year: 2007 end-page: 157 ident: bib0002 article-title: Prevalence and risk factors for erectile dysfunction in the US publication-title: Am J Med – volume: 11 start-page: 2546 year: 2014 ident: 10.1016/j.urology.2020.11.051_bib0011 article-title: Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients publication-title: J Sex Med doi: 10.1111/jsm.12647 – volume: 93 start-page: 679 year: 2017 ident: 10.1016/j.urology.2020.11.051_bib0012 article-title: Recent advances in the treatment of erectile dysfunction publication-title: Postgrad Med J doi: 10.1136/postgradmedj-2016-134073 – volume: 13 start-page: 465 year: 2016 ident: 10.1016/j.urology.2020.11.051_bib0014 article-title: Pharmacotherapy for erectile dysfunction: recommendations from the fourth international Consultation for Sexual Medicine (ICSM 2015) publication-title: J Sex Med doi: 10.1016/j.jsxm.2016.01.016 – ident: 10.1016/j.urology.2020.11.051_bib0018 – volume: 200 start-page: 633 year: 2018 ident: 10.1016/j.urology.2020.11.051_bib0001 article-title: Erectile dysfunction: AUA guideline publication-title: J Urol doi: 10.1016/j.juro.2018.05.004 – volume: 21 start-page: S143 year: 2018 ident: 10.1016/j.urology.2020.11.051_bib0010 article-title: PIH15: the economic burden of erectile dysfunction and related comorbidities: a Medicare perspective publication-title: Value Health doi: 10.1016/j.jval.2018.04.987 – volume: 120 start-page: 151 year: 2007 ident: 10.1016/j.urology.2020.11.051_bib0002 article-title: Prevalence and risk factors for erectile dysfunction in the US publication-title: Am J Med doi: 10.1016/j.amjmed.2006.06.010 – volume: 9 start-page: S116 issue: suppl 2 year: 2020 ident: 10.1016/j.urology.2020.11.051_bib0015 article-title: Current and future trends in men's health clinics publication-title: Transl Androl Urol doi: 10.21037/tau.2019.08.33 – volume: 73 start-page: e13384 year: 2019 ident: 10.1016/j.urology.2020.11.051_bib0008 article-title: The association of erectile dysfunction with productivity and absenteeism in eight countries globally publication-title: Int J Clin Pract doi: 10.1111/ijcp.13384 – volume: 2 start-page: 16003 year: 2016 ident: 10.1016/j.urology.2020.11.051_bib0020 article-title: Erectile dysfunction publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2016.3 – ident: 10.1016/j.urology.2020.11.051_bib0006 – volume: 102 start-page: 126 year: 2017 ident: 10.1016/j.urology.2020.11.051_bib0007 article-title: Assessing the variability in insurance coverage transparency for male sexual health conditions in the United States publication-title: Urology doi: 10.1016/j.urology.2016.12.031 – ident: 10.1016/j.urology.2020.11.051_bib0009 – volume: 199 start-page: e390 issue: 4S year: 2018 ident: 10.1016/j.urology.2020.11.051_bib0005 article-title: PD18-03 Doomed to impotence: analysis of erectile dysfunction (ED) and inflatable penile prosthesis (IPP) insurance coverage from verification benefits databases publication-title: J Urol doi: 10.1016/j.juro.2018.02.980 – volume: 16 start-page: 281 year: 2019 ident: 10.1016/j.urology.2020.11.051_bib0019 article-title: An update on: long-term outcomes of penile prostheses for the treatment of erectile dysfunction publication-title: Expert Rev Med Devices doi: 10.1080/17434440.2019.1598259 – year: 2019 ident: 10.1016/j.urology.2020.11.051_bib0004 – volume: 8 start-page: F1000 year: 2019 ident: 10.1016/j.urology.2020.11.051_bib0013 article-title: Recent advances in the understanding and management of erectile dysfunction publication-title: F1000Res doi: 10.12688/f1000research.16576.1 – volume: 7 start-page: 430 year: 2019 ident: 10.1016/j.urology.2020.11.051_bib0016 article-title: Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails publication-title: Sex Med Rev doi: 10.1016/j.sxmr.2018.11.007 – volume: 70 start-page: 1012 year: 2016 ident: 10.1016/j.urology.2020.11.051_bib0003 article-title: Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA publication-title: Int J Clin Pract doi: 10.1111/ijcp.12908 – volume: 6 start-page: 37 year: 2017 ident: 10.1016/j.urology.2020.11.051_bib0017 article-title: Penile prosthesis implant: scientific advances and technological innovations over the last four decades publication-title: Transl Androl Urol doi: 10.21037/tau.2016.12.06
SSID	ssj0006667
Score	2.453024
Snippet	To investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	140
SubjectTerms	Cross-Sectional Studies Erectile Dysfunction - economics Erectile Dysfunction - epidemiology Erectile Dysfunction - therapy Health Benefit Plans, Employee - economics Health Benefit Plans, Employee - statistics & numerical data Humans Insurance Claim Review - statistics & numerical data Insurance Coverage - economics Insurance Coverage - statistics & numerical data Male Middle Aged Penile Implantation - economics Penile Implantation - statistics & numerical data Phosphodiesterase 5 Inhibitors - economics Phosphodiesterase 5 Inhibitors - therapeutic use Prevalence
Title	An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0090429520314886 https://dx.doi.org/10.1016/j.urology.2020.11.051 https://www.ncbi.nlm.nih.gov/pubmed/33309705 https://www.proquest.com/docview/2470025978
Volume	149
WOSCitedRecordID	wos000627885200041&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1527-9995 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006667 issn: 0090-4295 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfKZTIS4qVKSOMkth8DdGJTKYi1Ut8i56a1dElJ02k880P4qxzHdtppmzYeeImitKdJej6fm88Fobe5T920T4nlMd-zPOGklkhkATMjWZCxII5F0zJ_SEcjNp3yb53OH1MLc7agRcHOz_nyv7IargGzZensP7C7_VG4AOfAdDgC2-F4K8aHxYVOI0Iu-VM5V0kKOFELqbf0FkFvoiL5g0bsLbLep18rqegaTIxNCnrTsUGmv4IIqU96ekZwZR3L5NpS5q_rWqbDYrWuWhRpi3dSqS5PMlQha8NMjs_IPrK3whAfZGxVbVSFVX2yrnptVPp7OReFWImqbD4-nlWzHxtMh6clKPqZylgTCYi44XYkw91K5TLC16UWGKxqlzu74pqR2KrLqZa5fdXv6ZIuUGGJub1W72nDLaWGsB3d4fZC7-3R1-hgMhxG48F0_G7505JjyeT2vZ7RsoP2XOpzEJt74eFgetQqe_D-mvk95jE3RWLvr7zzdebPde5NY-aMH6D72j_BocLVQ9TJikfo7hedgfEY_Q4LbOCFyxwLvIEXNvDCZYEBXngiT3Ns4IW34IU38MIALwzwwhJe-DK8sIIXbuH1BE0OBuOPny09yMNKvCCorX7gCEFTmudE0Dz1fBKznHiZzwShJOcuTRNwXFMG3wm4bFnnJ0SwgHtc-NwT5CnaLcoie46wJ7gfJxlniUM8EtM4DoTISZynoPIDSrvIM_9vlOgu93LYyiIy6YzzSLMlkmwBDzgCtnSR3ZItVZuXmwgCw7zI1DCD1o0AfDcRspZQG7nKeL0N6RuDkgiUgNzZE0VWrleR61HpvHDKuuiZgk_7GoQQh1PHf3EL6pfo3mZhvkK7dbXOXqM7yVk9W1X7aIdO2b5eAX8BcQzgFA
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+Analysis+of+a+Commercial+Database+on+the+Use+of+Erectile+Dysfunction+Treatments+for+Men+With+Employer-Sponsored+Health+Insurance&rft.jtitle=Urology+%28Ridgewood%2C+N.J.%29&rft.au=Burnett%2C+Arthur+L&rft.au=Rojanasarot%2C+Sirikan&rft.au=Amorosi%2C+Stacey+L&rft.date=2021-03-01&rft.issn=1527-9995&rft.eissn=1527-9995&rft.volume=149&rft.spage=140&rft_id=info:doi/10.1016%2Fj.urology.2020.11.051&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-4295&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-4295&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-4295&client=summon